
DNA methylation in Alzheimer’s Disease
DNA methylation as a mechanism, biomarker, and potential therapeutic target for Alzheimer’s disease.
Capture genetic and epigenetic information simultaneously in a single workflow to better understand normal and disease biology.
Current technologies are unable to simultaneously resolve both genetic and epigenetic sequences and miss important information. biomodal, helps you measure multiple modalities in a single workflow for highly accurate multiomic analysis in less time – and with only 10ng of DNA.
Combined epigenetic and genetic analysis in a single sequencing run lets you access the most critical information from your DNA samples.
Better characterise early stage cancer for diagnostic and therapy development.
Pinpoint epigenetic changes that determine patterns of disease and health throughout a lifespan.
See precisely how methylation states impact epigenetic changes at the population level.
Detect minute epigenetic changes to better understand maternal and foetal health.
Combined data reveals the role of methylation in neurodegeneration.
Improved DNA-based diagnostics with the ability to see disease-relevant changes from low input samples
DNA methylation as a mechanism, biomarker, and potential therapeutic target for Alzheimer’s disease.
John McShane recently joined biomodal as our Director of Business Development for Eastern North America and Canada.